Literature DB >> 19744853

Cardiac or cardiopulmonary transplantation in childhood cancer survivors: an increasing need?

Gill Levitt1, Antoinette Anazodo, Michael Burch, Kathryn Bunch.   

Abstract

Childhood cancer patients now have an excellent survival rate. Anthracyclines and radiation have contributed to this success, unfortunately at a cost. Both modalities are cardiotoxic and in some cases this is fatal unless treated by cardiac transplantation. This population-based study investigates the requirement for transplantation, patient demographics and transplant outcomes. Childhood cancer survivors requiring a subsequent cardiac or cardiopulmonary transplant were identified by record linkage between the National Registry Childhood Tumours (NRCT) and United Kingdom Transplant registry (UKT). The clinical details were obtained from the treatment centres for confirmed matches. Forty-three patients were identified as requiring cardiac transplantation: 36 underwent transplantation, 4 died while waiting and 3 were removed from the list. Their childhood cancers included 21 haematopoietic and 22 solid tumours diagnosed at a median age of 3.00 years (range 0.11-13.92 years). All patients were treated with anthracyclines (210-750 mg/m(2)) and 15 received cardiac radiation. The median age at cardiac transplantation was 14.80 years (range 3.26-23.92 years) and actuarial survival for the 36 who underwent cardiac transplantation was 74% and 67% at 5 and 10 years, respectively. A further three patients underwent heart/lung transplantation: all three died from transplant-related causes. Cardiac transplantation is a realistic option for cancer survivors, with survival rates comparable with those of other cardiac recipients. This study demonstrates that, over three decades, there has been an increased requirement for cardiac transplantation among childhood cancer survivors. Future planning for long term survivors needs to take this into account.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19744853     DOI: 10.1016/j.ejca.2009.08.006

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  15 in total

Review 1.  Adverse effects of treatment in childhood acute lymphoblastic leukemia: general overview and implications for long-term cardiac health.

Authors:  Kirsten K Ness; Saro H Armenian; Nina Kadan-Lottick; James G Gurney
Journal:  Expert Rev Hematol       Date:  2011-04       Impact factor: 2.929

Review 2.  Cardiovascular diseases in survivors of childhood cancer.

Authors:  Neha Bansal; Javier G Blanco; Umesh C Sharma; Saraswati Pokharel; Shannon Shisler; Steven E Lipshultz
Journal:  Cancer Metastasis Rev       Date:  2020-03       Impact factor: 9.264

3.  Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy.

Authors:  Steven E Lipshultz; David C Landy; Gabriela Lopez-Mitnik; Stuart R Lipsitz; Andrea S Hinkle; Louis S Constine; Carol A French; Amy M Rovitelli; Cindy Proukou; M Jacob Adams; Tracie L Miller
Journal:  J Clin Oncol       Date:  2012-03-05       Impact factor: 44.544

4.  Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes.

Authors:  Steven E Lipshultz; Tracie L Miller; Stuart R Lipsitz; Donna S Neuberg; Suzanne E Dahlberg; Steven D Colan; Lewis B Silverman; Jacqueline M Henkel; Vivian I Franco; Laura L Cushman; Barbara L Asselin; Luis A Clavell; Uma Athale; Bruno Michon; Caroline Laverdière; Marshall A Schorin; Eric Larsen; Naheed Usmani; Stephen E Sallan
Journal:  Pediatrics       Date:  2012-11-19       Impact factor: 7.124

5.  Anthracycline-associated cardiotoxicity in survivors of childhood cancer.

Authors:  Barry H Trachtenberg; David C Landy; Vivian I Franco; Jacqueline M Henkel; Elliot J Pearson; Tracie L Miller; Steven E Lipshultz
Journal:  Pediatr Cardiol       Date:  2011-01-09       Impact factor: 1.655

6.  Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.

Authors:  Steven E Lipshultz; Rebecca E Scully; Stuart R Lipsitz; Stephen E Sallan; Lewis B Silverman; Tracie L Miller; Elly V Barry; Barbara L Asselin; Uma Athale; Luis A Clavell; Eric Larsen; Albert Moghrabi; Yvan Samson; Bruno Michon; Marshall A Schorin; Harvey J Cohen; Donna S Neuberg; E John Orav; Steven D Colan
Journal:  Lancet Oncol       Date:  2010-09-16       Impact factor: 41.316

7.  Anthracycline-induced cardiotoxicity: a review of pathophysiology, diagnosis, and treatment.

Authors:  Shashi Raj; Vivian I Franco; Steven E Lipshultz
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-06

8.  Cardiac failure 30 years after treatment containing anthracycline for childhood acute lymphoblastic leukemia.

Authors:  John M Goldberg; Rebecca E Scully; Stephen E Sallan; Steven E Lipshultz
Journal:  J Pediatr Hematol Oncol       Date:  2012-07       Impact factor: 1.289

9.  Solid organ transplantation after treatment for childhood cancer: a retrospective cohort analysis from the Childhood Cancer Survivor Study.

Authors:  Andrew C Dietz; Kristy Seidel; Wendy M Leisenring; Daniel A Mulrooney; Jean M Tersak; Richard D Glick; Cathy A Burnweit; Daniel M Green; Lisa R Diller; Susan A Smith; Rebecca M Howell; Marilyn Stovall; Gregory T Armstrong; Kevin C Oeffinger; Leslie L Robison; Amanda M Termuhlen
Journal:  Lancet Oncol       Date:  2019-08-27       Impact factor: 41.316

10.  Cardiovascular effects in childhood cancer survivors treated with anthracyclines.

Authors:  Vivian I Franco; Jacqueline M Henkel; Tracie L Miller; Steven E Lipshultz
Journal:  Cardiol Res Pract       Date:  2011-02-10       Impact factor: 1.866

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.